Impact Factor
3.30
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.38
575 total citations
h5-index
30
h5 depth signal
Cited share
69.3%
176 of 254
Total citations
575
Citation footprint
Metric signal
2.46
External metric anchor
Self-citation
2.4%
14 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
607
United States
392
Italy
150
Japan
49
Germany
47
Citing Fields of Research
Cardiology
976
Diabetes
149
Physiology
146
Noncoding RNA
109
Immunology
98
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
14,653
Articles tracked across the journal lifetime
Indexed publication set
254
176 cited publications
Last 12 months
134
11.2 publications/month
Open access share
10.4%
14 OA publications in the last year
Leading citing country
China
607 citing publications
Leading citing field
Cardiology
976 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1979-
v1n1, 1979-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Broad Categories
Cardiology
Pharmacology
MeSH Descriptors
Cardiovascular Agents
Cardiovascular Diseases
Cardiovascular System
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/fjc.0000000000001893
Open DOI
Finerenone: A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome
Cardiovascular-kidney-metabolic (CKM) syndrome represents the interconnected pathophysiology of metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease, leading to multiorgan dysfunction and elevated adverse outc...
02
DOI 10.1097/fjc.0000000000001892
Open DOI
Fifty Years of Non-Adrenergic Inotropes in Heart Failure
03
DOI 10.1097/fjc.0000000000001891
Open DOI
Targeting Vascular Smooth Muscle Cell Senescence for Cardiovascular Pharmacology: Mechanisms and Therapeutic Perspectives
Vascular smooth muscle cells (VSMCs) play a central role in maintaining vascular tone, structural integrity, and adaptive remodeling. With aging and chronic cardiometabolic stress, however, VSMCs undergo senescence driven by telomere att...
04
DOI 10.1097/fjc.0000000000001890
Open DOI
Deubiquitinase OTUB1 attenuates pathological cardiac hypertrophy by activating the AMPK signaling pathway
Cardiac hypertrophy, a response to pathological stimuli, eventually progresses to heart failure. Ovarian tumor-associated proteinase B1 (OTUB1), a deubiquitinase of the ovarian tumor (OUT) family, regulates inflammation, cell survival, a...
05
DOI 10.1097/fjc.0000000000001888
Open DOI
Impact of Trimetazidine on Echocardiographic Indices and Clinical Outcomes in Ischemic Cardiomyopathy: An Updated Meta-Analysis of Clinical Trials
Ischemic cardiomyopathy (ICM) is a major cause of chronic heart failure with impaired left ventricular (LV) function. Trimetazidine, a metabolic modulator that shifts energy utilization from fatty acid oxidation to glucose oxidation, may...
06
DOI 10.1097/fjc.0000000000001887
Open DOI
Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications
Lipoprotein(a) [Lp(a)] is a genetically determined apolipoprotein B-containing lipoprotein independently associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Circulating Lp(a) concentr...
07
DOI 10.1097/fjc.0000000000001885
Open DOI
The Silent Window: Detecting Duchenne Cardiomyopathy Before Ejection Fraction Decline
Was not provided for this article.
08
DOI 10.1097/fjc.0000000000001886
Open DOI
Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cance...
09
DOI 10.1097/fjc.0000000000001882
Open DOI
One Month Versus Three Months of Aspirin After Percutaneous Coronary Intervention: A Reconstructed Time-to-Event Analysis
P2Y12-inhibitor monotherapy after abbreviated dual antiplatelet therapy (DAPT) reduces bleeding after percutaneous coronary intervention, but whether aspirin can be stopped after one month rather than three remains uncertain. We reconstr...
10
DOI 10.1097/fjc.0000000000001883
Open DOI
Upadacitinib and Cardiovascular Safety Across Immune-Mediated Inflammatory Diseases: Reassurance Without Certainty
Was not provided for this article.
Bibliographical & Catalog Notes
Place of publication varies.
Supplements accompany some vols.
Also issued online.
Vol. 7, no. 1 (1985)19900914 Notice not published Printed on acid-free paper